Abeona Therapeutics (ABEO) CFO sells 49,338 shares under 10b5-1 tax plan

Rhea-AI Filing Summary

Abeona Therapeutics’ Chief Financial Officer Joseph Walter Vazzano reported selling a total of 49,338 shares of common stock in open-market transactions on June 8–9, 2026 at weighted average prices around $5.30–$5.43 per share. According to the disclosure, these sales were made to cover tax obligations arising from the vesting of restricted stock awards and were carried out under a Rule 10b5-1 trading plan adopted on January 21, 2026. Following the transactions, Vazzano directly holds 518,437 shares of Abeona Therapeutics common stock.

Insider Trade Summary 10b5-1

Net Seller: 49,338 shares ($265,242)

Net Sell 3 txns

Insider Vazzano Joseph Walter

Role Chief Financial Officer

Sold 49,338 shs ($265K)

Type	Security	Shares	Price	Value
Sale	Common Stock	13,421	$5.3042	$71K
Sale	Common Stock	25,646	$5.3922	$138K
Sale	Common Stock	10,271	$5.4295	$56K

Holdings After Transaction: Common Stock — 544,083 shares (Direct, null)

Footnotes (1)

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.345 to $5.54 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.47 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 21, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.30 to $5.42 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Key Figures

Total shares sold: 49,338 shares June 9 sale block 1: 25,646 shares at $5.3922 June 9 sale block 2: 13,421 shares at $5.3042 +3 more

6 metrics

Total shares sold 49,338 shares Common stock sold by CFO on June 8–9, 2026

June 9 sale block 1 25,646 shares at $5.3922 Open-market sale of common stock

June 9 sale block 2 13,421 shares at $5.3042 Open-market sale of common stock

June 8 sale 10,271 shares at $5.4295 Open-market sale of common stock

Shares held after transactions 518,437 shares Direct ABEO common stock ownership by CFO

Net share direction 49,338 net shares sold Net-sell based on transaction summary

Key Terms

Rule 10b5-1 trading plan, restricted stock awards, weighted average price, open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock awards financial

"cover tax obligations associated with the vesting of restricted stock awards"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/09/2026 - 08:33 PM Accepted by SEC EDGAR 06/09/2026 - 08:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vazzano Joseph Walter

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OHIO 44103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/08/2026		S(1)		10,271	D	$5.4295(2)	557,504	D
Common Stock	06/09/2026		S(1)		13,421	D	$5.3042(3)	544,083	D
Common Stock	06/09/2026		S(4)		25,646	D	$5.3922(5)	518,437	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.345 to $5.54 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.47 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

4. The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 21, 2026.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.30 to $5.42 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Joseph Vazzano	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Abeona Therapeutics (ABEO) disclose in this Form 4 filing?

Abeona Therapeutics reported that CFO Joseph Walter Vazzano sold 49,338 ABEO common shares in open-market transactions. The filing states these sales were made to cover tax obligations tied to vesting restricted stock awards under a pre-arranged Rule 10b5-1 trading plan.

How many Abeona Therapeutics (ABEO) shares did the CFO sell and at what prices?

The CFO sold 49,338 ABEO common shares in three transactions at weighted average prices of $5.4295, $5.3922, and $5.3042. The filing explains that each reported price reflects multiple trades within stated intraday ranges rather than a single execution price.

Why did Abeona Therapeutics’ (ABEO) CFO sell shares according to the Form 4?

The Form 4 states the sales were executed to cover tax obligations arising from the vesting of restricted stock awards. This indicates the transactions were tied to compensation-related taxes rather than discretionary portfolio changes, as explicitly described in the filing footnotes.

Was the Abeona Therapeutics (ABEO) CFO’s stock sale pre-planned?

Yes. The filing notes the shares were sold under a Rule 10b5-1 trading plan adopted by the CFO on January 21, 2026. Such plans pre-schedule trades, reducing the significance of short-term market timing in evaluating these insider transactions.

How many Abeona Therapeutics (ABEO) shares does the CFO hold after these sales?

After the reported transactions, the CFO directly holds 518,437 shares of Abeona Therapeutics common stock. This post-transaction balance shows he retains a substantial equity position in ABEO despite selling shares to meet tax obligations linked to restricted stock vesting.

Do these Abeona Therapeutics (ABEO) insider sales indicate a large position change?

The CFO sold 49,338 shares while remaining directly invested with 518,437 shares after the trades. Based on the filing, the transactions represent a partial reduction mainly for tax purposes, rather than a complete or near-complete exit from his ABEO equity position.